Clinical trialNCT07491497RecruitingPhase 1/PHASE2Interventional

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

SponsorTRIANA Biomedicines, Inc.Enrollment160ALK-Positive Lung CancerALK-positive NSCLCALK-positive Non-small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Colorado Cancer Center
Aurora, Colorado, United States
Kyle Concannon, MD
Recruiting
Dana Farber Cancer Center
Boston, Massachusetts, United States
Alice Shaw, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Jessica Lin, MD
Recruiting
Washington University Medical Center
St Louis, Missouri, United States
Saiama Waqar, MD
Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Alexander Drilon, MD
Recruiting
Taylor Cancer Research Center
Maumee, Ohio, United States
John Nemunaitis, MD
Recruiting
Scri Oncology Partners
Nashville, Tennessee, United States
Melissa Johnson, MD
Recruiting
Start Mountain Region
West Valley City, Utah, United States
José Pacheco, MD
Recruiting
Next Virginia
Fairfax, Virginia, United States
Alexander Spira, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

3-(2-oxo-5-((3-phenyl-1,2,4-oxadiazol-5-yl)methyl)benzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Mar 2026
Primary completion: 31 May 2029
Completion: 30 Jan 2034
Last update posted: 16 Jun 2026
Registered enrollment: 160
Registry id: NCT07491497

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.